Business Context and Reporting Period
This Form 8-K is a current report filed by OncoCyte Corporation (trading symbol: OCX) on February 4, 2021. The filing discloses the entry into a material definitive agreement for an underwritten public offering of common stock. The company is an emerging growth company incorporated in California.
Key Financial Metrics and Transaction Details
- Offering Size: 7,780,000 shares of common stock.
- Public Offering Price: $4.50 per share.
- Gross Proceeds: $35,010,000 (before underwriting discounts and offering expenses).
- Over-Allotment Option: Underwriters granted an option to purchase up to 1,167,000 additional shares within 30 days.
- Expected Closing Date: On or about February 9, 2021.
The filing does not provide current revenue, profit, cash flow, margin, debt, or liquidity metrics for the company's ongoing operations.
Material Changes and Use of Proceeds
The primary material change is the capital raise intended to fund specific acquisitions and corporate obligations. The Company intends to use the net proceeds as follows:
- Chronix Biomedical, Inc. Acquisition: Payment of $2.675 million upon closing and other post-merger obligations, plus potential future milestone payments to former shareholders.
- Razor Genomics, Inc. Acquisition: Payment of all or a portion of the $10 million cash portion of the purchase price.
- Insight Genetics, Inc. Acquisition: Payment of all or a portion of the $6 million additional merger consideration contingent on meeting applicable milestones.
- General Corporate Purposes: Remaining proceeds may be used for working capital.
Guidance, Risks, and Management Commentary
Lock-Up Agreements: Certain officers and directors have entered into lock-up agreements prohibiting the sale or transfer of securities for 90 days from the date of the Purchase Agreement.
Risks and Contingencies: The filing includes forward-looking statements regarding the anticipated closing and proceeds. Risks include the Company's ability to satisfy closing conditions on a timely basis or at all. The Company cautions investors not to place undue reliance on these statements.
Legal Framework: The offering is made pursuant to an effective shelf registration statement on Form S-3. The Purchase Agreement includes customary representations, warranties, indemnification, and termination provisions.
Investor Verification Checklist
- Verify the final closing date of the offering and the actual net proceeds received after deducting underwriting discounts and expenses.
- Confirm the status of the Chronix Biomedical, Razor Genomics, and Insight Genetics acquisitions and whether milestone payments are triggered.
- Review the full Prospectus Supplement filed on February 4, 2021, for detailed risk factors and use of proceeds.
- Monitor the exercise of the 30-day over-allotment option by the underwriters.
- Check subsequent filings for any updates on the satisfaction of closing conditions.